首页 > 最新文献

CHEST critical care最新文献

英文 中文
Time Is Brain 时间就是大脑
Pub Date : 2024-09-06 DOI: 10.1016/j.chstcc.2024.100099
Giulia M. Benedetti MD , Lindsey A. Morgan MD , Dana B. Harrar MD, PhD
Status epilepticus (SE) is a life-threatening emergency that requires prompt recognition and treatment and is common in the ICU. The definition of SE has evolved, with a shift toward highlighting the potential for permanent neurologic injury and prioritizing early termination. Although EEG serves a confirmatory role in the diagnosis of convulsive SE, SE in the ICU often is nonconvulsive, making EEG essential for diagnosis and management. In this review, we characterize the neurobiology of SE and provide clinically applicable strategies for timely recognition and effective treatment of SE, highlighting ICU-level therapies and integration of continuous EEG. We also discuss the simultaneous etiologic evaluation that must take place to identify the cause of SE.
癫痫状态(SE)是一种危及生命的急症,需要及时识别和治疗,在重症监护病房很常见。癫痫状态的定义也在不断演变,目前已转向强调永久性神经损伤的可能性和优先考虑早期终止治疗。虽然脑电图在惊厥性 SE 的诊断中起着确诊作用,但 ICU 中的 SE 通常是非惊厥性的,因此脑电图对诊断和管理至关重要。在这篇综述中,我们描述了 SE 的神经生物学特征,并提供了及时识别和有效治疗 SE 的临床适用策略,重点介绍了 ICU 级别疗法和连续脑电图的整合。我们还讨论了为确定 SE 病因而必须同时进行的病因学评估。
{"title":"Time Is Brain","authors":"Giulia M. Benedetti MD ,&nbsp;Lindsey A. Morgan MD ,&nbsp;Dana B. Harrar MD, PhD","doi":"10.1016/j.chstcc.2024.100099","DOIUrl":"10.1016/j.chstcc.2024.100099","url":null,"abstract":"<div><div>Status epilepticus (SE) is a life-threatening emergency that requires prompt recognition and treatment and is common in the ICU. The definition of SE has evolved, with a shift toward highlighting the potential for permanent neurologic injury and prioritizing early termination. Although EEG serves a confirmatory role in the diagnosis of convulsive SE, SE in the ICU often is nonconvulsive, making EEG essential for diagnosis and management. In this review, we characterize the neurobiology of SE and provide clinically applicable strategies for timely recognition and effective treatment of SE, highlighting ICU-level therapies and integration of continuous EEG. We also discuss the simultaneous etiologic evaluation that must take place to identify the cause of SE.</div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 4","pages":"Article 100099"},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) 治疗 COVID-19 的免疫调节剂随机主方案(ACTIV-1 IM)中的资源使用情况
Pub Date : 2024-08-22 DOI: 10.1016/j.chstcc.2024.100095
Anne M. Lachiewicz MD, MPH , Miloni Shah MPH , Tatyana Der MD , Derek Cyr PhD , Hussein R. Al-Khalidi PhD , Christopher Lindsell PhD , Vivek Iyer MD , Akram Khan MD , Reynold Panettieri MD , Adriana M. Rauseo MD , Martin Maillo MD , Andreas Schmid MD , Sugeet Jagpal MD , William G. Powderly MD , Samuel A. Bozzette MD, PhD , Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) Study Group

Background

COVID-19 pneumonia requires considerable health care resources.

Research Question

Does a single dose of infliximab or abatacept, in addition to remdesivir and steroids, decreased resource use among patients hospitalized with COVID-19 pneumonia?

Study Design and Methods

The Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) was a randomized, placebo-controlled trial examining the potential benefit in time to recovery and mortality of the immunomodulators infliximab, abatacept, and cenicriviroc. This observational study performed a secondary analysis of the participants receiving infliximab, abatacept, and common placebo to examine resource use. Hospital days, ICU days, days with supplemental oxygen, days with high-flow nasal cannula or noninvasive ventilation, ventilator days, and days of extracorporeal membrane oxygenation each were examined. Proportional odds models were used to compare days alive and free of resource use over 28 days between infliximab and placebo groups and between abatacept and placebo groups.

Results

In this study, infliximab infusion, compared with placebo, was associated with greater odds of being alive and free of all interventions tested. Abatacept use was associated only with greater odds of days alive and free of hospitalization and supplemental oxygen.

Interpretation

Infliximab and abatacept use were associated with decreased use of health care resources over 28 days compared with placebo, but the absolute differences were small.

Clinical Trial Registry

ClinicalTrials.gov; No.: NCT04593940; URL: www.clinicaltrials.gov
背景COVID-19肺炎需要大量医疗资源。研究问题除了雷米替韦和类固醇外,单剂量英夫利昔单抗或阿巴他赛能减少COVID-19肺炎住院患者的资源使用吗?研究设计与方法治疗 COVID-19 的免疫调节剂随机主方案(ACTIV-1 IM)是一项随机、安慰剂对照试验,目的是研究免疫调节剂英夫利昔单抗、阿巴他赛普和西尼瑞洛对康复时间和死亡率的潜在益处。这项观察性研究对接受英夫利昔单抗、阿巴他赛普和普通安慰剂的参与者进行了二次分析,以检查资源使用情况。对住院天数、重症监护室天数、使用补充氧气天数、使用高流量鼻插管或无创通气天数、使用呼吸机天数以及使用体外膜肺氧合的天数进行了研究。结果 在这项研究中,与安慰剂相比,输注英夫利昔单抗与更高的存活几率和免于所有测试干预的几率相关。解释与安慰剂相比,使用英夫利昔单抗和阿巴他赛普可减少28天内医疗资源的使用,但绝对差异很小。临床试验注册中心ClinicalTrials.gov; No.
{"title":"Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM)","authors":"Anne M. Lachiewicz MD, MPH ,&nbsp;Miloni Shah MPH ,&nbsp;Tatyana Der MD ,&nbsp;Derek Cyr PhD ,&nbsp;Hussein R. Al-Khalidi PhD ,&nbsp;Christopher Lindsell PhD ,&nbsp;Vivek Iyer MD ,&nbsp;Akram Khan MD ,&nbsp;Reynold Panettieri MD ,&nbsp;Adriana M. Rauseo MD ,&nbsp;Martin Maillo MD ,&nbsp;Andreas Schmid MD ,&nbsp;Sugeet Jagpal MD ,&nbsp;William G. Powderly MD ,&nbsp;Samuel A. Bozzette MD, PhD ,&nbsp;Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) Study Group","doi":"10.1016/j.chstcc.2024.100095","DOIUrl":"10.1016/j.chstcc.2024.100095","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 pneumonia requires considerable health care resources.</div></div><div><h3>Research Question</h3><div>Does a single dose of infliximab or abatacept, in addition to remdesivir and steroids, decreased resource use among patients hospitalized with COVID-19 pneumonia?</div></div><div><h3>Study Design and Methods</h3><div>The Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) was a randomized, placebo-controlled trial examining the potential benefit in time to recovery and mortality of the immunomodulators infliximab, abatacept, and cenicriviroc. This observational study performed a secondary analysis of the participants receiving infliximab, abatacept, and common placebo to examine resource use. Hospital days, ICU days, days with supplemental oxygen, days with high-flow nasal cannula or noninvasive ventilation, ventilator days, and days of extracorporeal membrane oxygenation each were examined. Proportional odds models were used to compare days alive and free of resource use over 28 days between infliximab and placebo groups and between abatacept and placebo groups.</div></div><div><h3>Results</h3><div>In this study, infliximab infusion, compared with placebo, was associated with greater odds of being alive and free of all interventions tested. Abatacept use was associated only with greater odds of days alive and free of hospitalization and supplemental oxygen.</div></div><div><h3>Interpretation</h3><div>Infliximab and abatacept use were associated with decreased use of health care resources over 28 days compared with placebo, but the absolute differences were small.</div></div><div><h3>Clinical Trial Registry</h3><div>ClinicalTrials.gov; No.: NCT04593940; URL: <span><span>www.clinicaltrials.gov</span><svg><path></path></svg></span></div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 4","pages":"Article 100095"},"PeriodicalIF":0.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulatory Extracorporeal Membrane Oxygenation Support for High-Risk Acute Pulmonary Embolism 体外膜氧合循环支持治疗高风险急性肺栓塞
Pub Date : 2024-08-17 DOI: 10.1016/j.chstcc.2024.100096
Salman Abdulaziz MBBS, FRCP , Vivek Kakar MD, FRCA , Huda Alfoudri MBChB, FCARCSI , Mohammed Shalaby MD , Mikaela V. Allen NMD , Shameena Beegom RN, MSc , John F. Fraser MBChB, PhD, FRCP, FRCA, FFARCSI, FCICM, FELSO , Saleh Fares Al Ali MD, MPH
High-risk pulmonary embolism (PE), defined as obstruction of the pulmonary arterial tree that leads to hemodynamic instability, is a common cause of cardiac arrest, with a mortality rate of up to 50%. The obstruction of the pulmonary circulation interferes with gas exchange and causes hemodynamic disturbances in both the right and left sides of the heart. Some international guidelines have suggested the use of extracorporeal membrane oxygenation (ECMO), in combination with definitive therapy, in patients with PE with refractory circulatory collapse or cardiac arrest. Furthermore, several observational studies have shown that ECMO may be beneficial in stabilizing patients with high-risk PE, especially as a form of bridging therapy in patients for whom common reperfusion methods may be insufficient or have delayed efficacy. We present the case of a patient with acute high-risk PE and the role of ECMO in addressing the physiologic derangements caused by PE and improving patient outcomes. We reviewed the literature reporting the experience on ECMO use in conjunction with various forms of definitive treatment for PE. We describe the various ECMO cannulation strategies applicable for patients with high-risk PE, the role of adjunct mechanical circulatory support, practical guidance on ECMO weaning, and the interaction between the PE response team and the ECMO team in the setting of high-risk PE.
高危肺栓塞(PE)是指导致血液动力学不稳定的肺动脉树阻塞,是心脏骤停的常见原因,死亡率高达 50%。肺循环受阻会影响气体交换,导致心脏左右两侧血流动力学紊乱。一些国际指南建议,对于出现难治性循环衰竭或心跳骤停的 PE 患者,可使用体外膜肺氧合(ECMO),并结合确定性疗法。此外,一些观察性研究表明,ECMO 有助于稳定高危 PE 患者的病情,尤其是作为一种桥接疗法,用于普通再灌注方法可能不足或疗效延迟的患者。我们介绍了一名急性高危 PE 患者的病例,以及 ECMO 在解决 PE 引起的生理失调和改善患者预后方面的作用。我们回顾了有关 ECMO 与各种形式的 PE 最终治疗结合使用的文献。我们介绍了适用于高危 PE 患者的各种 ECMO 插管策略、辅助机械循环支持的作用、ECMO 断流的实用指南以及 PE 反应团队与 ECMO 团队在高危 PE 情况下的互动。
{"title":"Circulatory Extracorporeal Membrane Oxygenation Support for High-Risk Acute Pulmonary Embolism","authors":"Salman Abdulaziz MBBS, FRCP ,&nbsp;Vivek Kakar MD, FRCA ,&nbsp;Huda Alfoudri MBChB, FCARCSI ,&nbsp;Mohammed Shalaby MD ,&nbsp;Mikaela V. Allen NMD ,&nbsp;Shameena Beegom RN, MSc ,&nbsp;John F. Fraser MBChB, PhD, FRCP, FRCA, FFARCSI, FCICM, FELSO ,&nbsp;Saleh Fares Al Ali MD, MPH","doi":"10.1016/j.chstcc.2024.100096","DOIUrl":"10.1016/j.chstcc.2024.100096","url":null,"abstract":"<div><div>High-risk pulmonary embolism (PE), defined as obstruction of the pulmonary arterial tree that leads to hemodynamic instability, is a common cause of cardiac arrest, with a mortality rate of up to 50%. The obstruction of the pulmonary circulation interferes with gas exchange and causes hemodynamic disturbances in both the right and left sides of the heart. Some international guidelines have suggested the use of extracorporeal membrane oxygenation (ECMO), in combination with definitive therapy, in patients with PE with refractory circulatory collapse or cardiac arrest. Furthermore, several observational studies have shown that ECMO may be beneficial in stabilizing patients with high-risk PE, especially as a form of bridging therapy in patients for whom common reperfusion methods may be insufficient or have delayed efficacy. We present the case of a patient with acute high-risk PE and the role of ECMO in addressing the physiologic derangements caused by PE and improving patient outcomes. We reviewed the literature reporting the experience on ECMO use in conjunction with various forms of definitive treatment for PE. We describe the various ECMO cannulation strategies applicable for patients with high-risk PE, the role of adjunct mechanical circulatory support, practical guidance on ECMO weaning, and the interaction between the PE response team and the ECMO team in the setting of high-risk PE.</div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 4","pages":"Article 100096"},"PeriodicalIF":0.0,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142553387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reshaping Postpandemic Critical Care Collaboration in the Asia-Pacific Region 重塑亚太地区大流行后的重症监护合作
Pub Date : 2024-08-10 DOI: 10.1016/j.chstcc.2024.100094
Eamon P. Raith MBBS, PhD, FCICM , See Kay Choong , Mark Nicholls , Wong Wai Tat , Sheila Nainan Myatra , Erwin Pradian MD, PhD , Moritoki Egi MD, PhD , Gee-Young Suh MD, PhD , Shanti Rudra Deva , Naranpurev Mendsaikhan , Shital Adhikari , Jose Melanio Grayda , Ming-Cheng Chan , Suthat Rungruanghiranya , Sean Loh FCCP, FRCP , David Ku FCICM
The COVID-19 pandemic presented the greatest challenge to modern intensive care medicine since its founding as a specialty in 1952, with its effects felt across health care services in all regions, including low-resourced settings. A paucity of data remains regarding the provision of intensive care medicine across the globe, particularly after the COVID-19 pandemic. To determine the broad state of critical care medicine after the pandemic in the Asia-Pacific region, the inaugural Asia-Pacific Critical Care Societies Summit was held in Singapore as a satellite meeting of the Asia-Pacific Intensive Care Symposium on August 18, 2023. This article summarizes this summit and provides key health and economic data for representative countries before detailing the resolutions and planned actions arising from this initiative. Fourteen critical care societies participated in the inaugural summit and consented to publication of societal reports. Common challenges and priorities for participating societies included issues around education and training, specialty and workforce advocacy, and collaboration and research. As a result of this summit, societies resolved to establish an Asia-Pacific education forum, to encourage the development of Asia-Pacific critical care trials, and to support engagement in multinational studies. A second Asia-Pacific Critical Care Societies Summit will be convened in 2024, with a focus on safety and quality challenges within ICUs represented by the societies present and discussion of the listed priority areas.
COVID-19 大流行是现代重症医学自 1952 年作为一个专科成立以来面临的最大挑战,其影响波及所有地区的医疗保健服务,包括资源匮乏的环境。有关全球重症医学服务的数据仍然匮乏,尤其是在 COVID-19 大流行之后。为了确定大流行后亚太地区重症监护医学的总体状况,首届亚太地区重症监护学会峰会作为亚太地区重症监护研讨会的卫星会议于 2023 年 8 月 18 日在新加坡举行。本文对此次峰会进行了总结,并提供了具有代表性的国家的主要健康和经济数据,然后详细介绍了此次峰会的决议和计划采取的行动。14 个重症监护学会参加了首届峰会,并同意发表学会报告。与会学会面临的共同挑战和优先事项包括教育和培训、专科和劳动力宣传以及合作与研究等方面的问题。通过此次峰会,各学会决心建立亚太地区教育论坛,鼓励亚太地区重症监护试验的发展,并支持参与多国研究。第二届亚太地区重症监护学会峰会将于 2024 年召开,重点关注与会学会所代表的 ICU 在安全和质量方面所面临的挑战,并对所列优先领域进行讨论。
{"title":"Reshaping Postpandemic Critical Care Collaboration in the Asia-Pacific Region","authors":"Eamon P. Raith MBBS, PhD, FCICM ,&nbsp;See Kay Choong ,&nbsp;Mark Nicholls ,&nbsp;Wong Wai Tat ,&nbsp;Sheila Nainan Myatra ,&nbsp;Erwin Pradian MD, PhD ,&nbsp;Moritoki Egi MD, PhD ,&nbsp;Gee-Young Suh MD, PhD ,&nbsp;Shanti Rudra Deva ,&nbsp;Naranpurev Mendsaikhan ,&nbsp;Shital Adhikari ,&nbsp;Jose Melanio Grayda ,&nbsp;Ming-Cheng Chan ,&nbsp;Suthat Rungruanghiranya ,&nbsp;Sean Loh FCCP, FRCP ,&nbsp;David Ku FCICM","doi":"10.1016/j.chstcc.2024.100094","DOIUrl":"10.1016/j.chstcc.2024.100094","url":null,"abstract":"<div><div>The COVID-19 pandemic presented the greatest challenge to modern intensive care medicine since its founding as a specialty in 1952, with its effects felt across health care services in all regions, including low-resourced settings. A paucity of data remains regarding the provision of intensive care medicine across the globe, particularly after the COVID-19 pandemic. To determine the broad state of critical care medicine after the pandemic in the Asia-Pacific region, the inaugural Asia-Pacific Critical Care Societies Summit was held in Singapore as a satellite meeting of the Asia-Pacific Intensive Care Symposium on August 18, 2023. This article summarizes this summit and provides key health and economic data for representative countries before detailing the resolutions and planned actions arising from this initiative. Fourteen critical care societies participated in the inaugural summit and consented to publication of societal reports. Common challenges and priorities for participating societies included issues around education and training, specialty and workforce advocacy, and collaboration and research. As a result of this summit, societies resolved to establish an Asia-Pacific education forum, to encourage the development of Asia-Pacific critical care trials, and to support engagement in multinational studies. A second Asia-Pacific Critical Care Societies Summit will be convened in 2024, with a focus on safety and quality challenges within ICUs represented by the societies present and discussion of the listed priority areas.</div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 4","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142659378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Medical Mistrust Among Surrogate Decision-Makers of Patients in the ICU at High Risk of Death 重症监护室高危死亡患者的代理决策者对医疗不信任的预测因素
Pub Date : 2024-08-08 DOI: 10.1016/j.chstcc.2024.100092
Scott T. Vasher MD, MSCR , Jeff Laux PhD , Shannon S. Carson MD , Blair Wendlandt MD, MSCR

Background

Medical mistrust may worsen communication between ICU surrogate decision-makers and intensivists. The prevalence of and risk factors for medical mistrust among surrogate decision-makers are not known.

Research Question

What are the potential sociodemographic risk factors for high medical mistrust among surrogate decision-makers of critically ill patients at high risk of death?

Study Design and Methods

In this pilot cross-sectional study conducted at a single academic medical center between August 2022 and August 2023, adult patients admitted to the medical ICU and their surrogate decision-makers were enrolled. All patients were incapacitated at enrollment with Sequential Organ Failure Assessment scores of ≥ 7 or required mechanical ventilation with vasopressor infusion. Surrogate decision-maker sociodemographic characteristics were age, race, sex, education, relationship to the patient, employment, prior exposure to a loved one transitioning to hospice or comfort-focused care, and religiousness. The primary outcome was surrogate decision-maker medical mistrust, measured using the Medical Mistrust Multiformat Scale. Multiple linear regression was used to determine sociodemographic characteristics associated with higher medical mistrust.

Results

Thirty-one patients and their surrogate decision-makers were enrolled during the study period, surpassing our goal of 30 pairs and indicating recruitment feasibility. Mean ± SD surrogate age was 53.8 ± 14.5 years, 24 surrogates were female, and mean medical mistrust score was 17.1 ± 5.4. Race was associated with medical mistrust, with Black participants showing higher medical mistrust compared with White participants (β =10.21; 95% CI, 3.40-17.02; P = .010). Religiousness was associated with lower medical mistrust (β = –2.94; 95% CI, –4.43 to –1.41; P = .003). Prior exposure to hospice or comfort-focused care was associated with higher medical mistrust (β = 7.06; 95% CI, 1.21-12.91; P = .025).

Interpretation

We found that recruiting ICU surrogates and measuring medical mistrust within 48 h of ICU admission was feasible. Several surrogate sociodemographic characteristics were associated with changes in medical mistrust. These preliminary findings will inform the design of future studies.
研究背景医疗不信任可能会恶化重症监护室代理决策者与重症监护医师之间的沟通。研究问题死亡风险高的重症患者的代理决策者对医疗不信任的潜在社会人口风险因素是什么?研究设计和方法这项试点横断面研究于 2022 年 8 月至 2023 年 8 月在一家学术医疗中心进行,研究对象为入住内科 ICU 的成年患者及其代理决策者。所有患者在入组时均无行为能力,器官功能衰竭序列评估评分≥7分,或需要输注血管加压素进行机械通气。代理决策者的社会人口学特征包括年龄、种族、性别、教育程度、与患者的关系、就业情况、是否曾接触过过渡到临终关怀或舒适护理的亲人以及宗教信仰。主要结果是代理决策者对医疗的不信任,使用医疗不信任多形式量表进行测量。多重线性回归用于确定与较高医疗不信任度相关的社会人口学特征。结果在研究期间,有31名患者及其代理决策者加入了研究,超过了我们设定的30对的目标,这表明招募是可行的。代理决策者的平均年龄为(53.8 ± 14.5)岁,24 人为女性,平均医疗不信任度为(17.1 ± 5.4)分。种族与医疗不信任度有关,黑人参与者的医疗不信任度高于白人参与者(β =10.21; 95% CI, 3.40-17.02; P = .010)。宗教信仰与较低的医疗不信任度相关(β = -2.94; 95% CI, -4.43 to -1.41; P = .003)。我们发现,在 ICU 入院 48 小时内招募 ICU 代理患者并测量医疗不信任度是可行的。一些代用的社会人口学特征与医疗不信任的变化有关。这些初步发现将为今后的研究设计提供参考。
{"title":"Predictors of Medical Mistrust Among Surrogate Decision-Makers of Patients in the ICU at High Risk of Death","authors":"Scott T. Vasher MD, MSCR ,&nbsp;Jeff Laux PhD ,&nbsp;Shannon S. Carson MD ,&nbsp;Blair Wendlandt MD, MSCR","doi":"10.1016/j.chstcc.2024.100092","DOIUrl":"10.1016/j.chstcc.2024.100092","url":null,"abstract":"<div><h3>Background</h3><div>Medical mistrust may worsen communication between ICU surrogate decision-makers and intensivists. The prevalence of and risk factors for medical mistrust among surrogate decision-makers are not known.</div></div><div><h3>Research Question</h3><div>What are the potential sociodemographic risk factors for high medical mistrust among surrogate decision-makers of critically ill patients at high risk of death?</div></div><div><h3>Study Design and Methods</h3><div>In this pilot cross-sectional study conducted at a single academic medical center between August 2022 and August 2023, adult patients admitted to the medical ICU and their surrogate decision-makers were enrolled. All patients were incapacitated at enrollment with Sequential Organ Failure Assessment scores of ≥ 7 or required mechanical ventilation with vasopressor infusion. Surrogate decision-maker sociodemographic characteristics were age, race, sex, education, relationship to the patient, employment, prior exposure to a loved one transitioning to hospice or comfort-focused care, and religiousness. The primary outcome was surrogate decision-maker medical mistrust, measured using the Medical Mistrust Multiformat Scale. Multiple linear regression was used to determine sociodemographic characteristics associated with higher medical mistrust.</div></div><div><h3>Results</h3><div>Thirty-one patients and their surrogate decision-makers were enrolled during the study period, surpassing our goal of 30 pairs and indicating recruitment feasibility. Mean ± SD surrogate age was 53.8 ± 14.5 years, 24 surrogates were female, and mean medical mistrust score was 17.1 ± 5.4. Race was associated with medical mistrust, with Black participants showing higher medical mistrust compared with White participants (β =10.21; 95% CI, 3.40-17.02; <em>P</em> = .010). Religiousness was associated with lower medical mistrust (β = –2.94; 95% CI, –4.43 to –1.41; <em>P = .</em>003). Prior exposure to hospice or comfort-focused care was associated with higher medical mistrust (β = 7.06; 95% CI, 1.21-12.91; <em>P = .</em>025).</div></div><div><h3>Interpretation</h3><div>We found that recruiting ICU surrogates and measuring medical mistrust within 48 h of ICU admission was feasible. Several surrogate sociodemographic characteristics were associated with changes in medical mistrust. These preliminary findings will inform the design of future studies.</div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 4","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142538303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The SONIC CENTRAL Study SONIC CENTRAL 研究
Pub Date : 2024-08-08 DOI: 10.1016/j.chstcc.2024.100091
Tessa A. Mulder MD , Linda Becude MD , Jorge E. Lopez Matta MD , Wilbert B. van den Hout PhD , David J. van Westerloo MD, PhD , Martijn P. Bauer MD, PhD

Background

Estimating central venous pressure (CVP) is essential in the diagnostic evaluation and treatment guidance of most hospitalized patients. It is unknown how different noninvasive bedside methods to estimate CVP correlate with each other and which method has the best accuracy.

Research Question

Which noninvasive bedside method to estimate CVP has the best accuracy to detect elevated CVP?

Study Design and Methods

During this prospective, single-center, observational study, we included patients admitted to the ward or ICU who already had an indwelling central venous catheter and who did not undergo positive pressure ventilation. We measured height of the fluid column in the external jugular vein (EJV) according to the Lewis and Borst method (EJV height), maximum and minimum diameters and height of the fluid column of the internal jugular vein (IJV; IJV height) using ultrasound, and diameters of the inferior vena cava (IVC) throughout a respiratory cycle and sniffing. We then compared these measurements with intravenously measured CVP.

Results

Ninety patients were included. Twenty-seven patients (30%) showed CVP of ≥ 10 mm Hg. All measurements had a significant correlation with CVP, except for the diameter of the IJV. Areas under the receiver operating characteristic curve for IJV height, EJV height, maximum diameter, and collapsibility on inspiration of the IVC were 0.85, 0.80, 0.78, and 0.76 respectively. The interobserver agreement was good to excellent. We estimated continuous likelihood ratios for the measurements to aid clinical decision-making.

Interpretation

Our results indicated that EJV height, IJV height, IVC diameter, and IVC collapsibility can be used to identify an elevated CVP in hospitalized patients. Among these, ultrasonographic estimation of the height of the fluid column in the IJV is quick and easy and allows identification of an elevated CVP with the best reproducibility and accuracy.

Clinical Trial Registration

National Trial Register; ID: NL-OMON22937; URL: https://onderzoekmetmensen.nl/en/trial/22937
背景估计中心静脉压(CVP)对于大多数住院患者的诊断评估和治疗指导至关重要。研究设计和方法在这项前瞻性、单中心、观察性研究中,我们纳入了已留置中心静脉导管且未接受正压通气的病房或重症监护室住院患者。我们根据刘易斯和博斯特法测量了颈外静脉(EJV)液柱的高度(EJV 高度),使用超声波测量了颈内静脉(IJV;IJV 高度)液柱的最大和最小直径和高度,以及下腔静脉(IVC)在整个呼吸周期和嗅闻过程中的直径。然后,我们将这些测量结果与静脉测量的 CVP 进行比较。27 名患者(30%)的 CVP ≥ 10 毫米汞柱。除 IJV 直径外,所有测量值均与 CVP 显著相关。IJV 高度、EJV 高度、最大直径和吸气时 IVC 的塌陷度的接收器操作特征曲线下面积分别为 0.85、0.80、0.78 和 0.76。观察者之间的一致性良好到极佳。我们估算了测量值的连续似然比,以帮助临床决策。解释我们的结果表明,EJV 高度、IJV 高度、IVC 直径和 IVC 塌陷度可用于识别住院患者的 CVP 升高。其中,用超声波估测 IJV 液柱高度既快速又简便,可用于识别 CVP 升高,且重现性和准确性最佳:NL-OMON22937; url: https://onderzoekmetmensen.nl/en/trial/22937
{"title":"The SONIC CENTRAL Study","authors":"Tessa A. Mulder MD ,&nbsp;Linda Becude MD ,&nbsp;Jorge E. Lopez Matta MD ,&nbsp;Wilbert B. van den Hout PhD ,&nbsp;David J. van Westerloo MD, PhD ,&nbsp;Martijn P. Bauer MD, PhD","doi":"10.1016/j.chstcc.2024.100091","DOIUrl":"10.1016/j.chstcc.2024.100091","url":null,"abstract":"<div><h3>Background</h3><div>Estimating central venous pressure (CVP) is essential in the diagnostic evaluation and treatment guidance of most hospitalized patients. It is unknown how different noninvasive bedside methods to estimate CVP correlate with each other and which method has the best accuracy.</div></div><div><h3>Research Question</h3><div>Which noninvasive bedside method to estimate CVP has the best accuracy to detect elevated CVP?</div></div><div><h3>Study Design and Methods</h3><div>During this prospective, single-center, observational study, we included patients admitted to the ward or ICU who already had an indwelling central venous catheter and who did not undergo positive pressure ventilation. We measured height of the fluid column in the external jugular vein (EJV) according to the Lewis and Borst method (EJV height), maximum and minimum diameters and height of the fluid column of the internal jugular vein (IJV; IJV height) using ultrasound, and diameters of the inferior vena cava (IVC) throughout a respiratory cycle and sniffing. We then compared these measurements with intravenously measured CVP.</div></div><div><h3>Results</h3><div>Ninety patients were included. Twenty-seven patients (30%) showed CVP of ≥ 10 mm Hg. All measurements had a significant correlation with CVP, except for the diameter of the IJV. Areas under the receiver operating characteristic curve for IJV height, EJV height, maximum diameter, and collapsibility on inspiration of the IVC were 0.85, 0.80, 0.78, and 0.76 respectively. The interobserver agreement was good to excellent. We estimated continuous likelihood ratios for the measurements to aid clinical decision-making.</div></div><div><h3>Interpretation</h3><div>Our results indicated that EJV height, IJV height, IVC diameter, and IVC collapsibility can be used to identify an elevated CVP in hospitalized patients. Among these, ultrasonographic estimation of the height of the fluid column in the IJV is quick and easy and allows identification of an elevated CVP with the best reproducibility and accuracy.</div></div><div><h3>Clinical Trial Registration</h3><div>National Trial Register; ID: NL-OMON22937; URL: <span><span>https://onderzoekmetmensen.nl/en/trial/22937</span><svg><path></path></svg></span></div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 4","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of In-Hospital Administration of a Tool to Predict Persistent Post-ICU Functional Impairment Among Older ICU Survivors 院内使用工具预测重症监护室老年幸存者重症监护室术后持续功能障碍的可行性
Pub Date : 2024-08-08 DOI: 10.1016/j.chstcc.2024.100093
Julia A. Stevenson BA , Terrence E. Murphy PhD , Baylah Tessier-Sherman MPH , Margaret A. Pisani MD, MPH , Thomas M. Gill MD , Lauren E. Ferrante MD, MHS

Background

A recent international consensus conference called for the development of risk prediction models to identify ICU survivors at increased risk of each of the post-ICU syndrome domains. We previously developed and validated a risk prediction tool for functional impairment after ICU admission among older adults.

Research Question

In this pilot study, we assessed the feasibility of administering the risk prediction tool in the hospital to older adults who had just survived critical illness. An exploratory objective was to evaluate whether augmentation of the model with additional hospital-related factors improved discrimination.

Study Design and Methods

Between January and October 2020, 50 adults aged 65 years and older underwent in-hospital administration of the risk prediction tool. Survivors were called monthly for 6 months after discharge. Feasibility was defined as completion of all tool components by ≥ 70% of enrolled participants. Persistent functional impairment was defined as failure to return to the functional baseline from before the ICU stay at the 6-month interview based on seven daily activities. The model was sequentially refit after adding three in-hospital factors as predictors, one at a time and then all together. Model discrimination was assessed with receiver operating characteristic curves.

Results

The tool met the a priori feasibility threshold, with 92.0% of enrolled participants completing all eight components. In the exploratory analysis, the addition of Acute Physiology and Chronic Health Evaluation II score, presence of delirium, and maximum in-hospital mobility resulted in a 5% gain in discrimination that did not achieve statistical significance (area under the receiver operating characteristic curve, 0.75; 95% CI, 0.68-0.82; P = .09).

Interpretation

Our results indicate that the risk prediction tool is feasible for use in the hospital setting, enabling the identification of ICU survivors at high risk of persistent functional impairment at 6 months after discharge. Augmentation with hospital-related factors improved model discrimination, but did not achieve statistical significance in this pilot study. Future studies should evaluate the augmented model in larger cohorts.
背景最近召开的一次国际共识会议呼吁开发风险预测模型,以识别ICU幸存者患ICU后综合征各领域风险增加的情况。研究问题在这项试验性研究中,我们评估了在医院对刚从危重病中存活下来的老年人使用风险预测工具的可行性。研究设计和方法在 2020 年 1 月至 10 月期间,50 名 65 岁及以上的成年人在医院内使用了风险预测工具。在出院后的 6 个月内,每月给幸存者打电话。可行性定义为≥70%的注册参与者完成了所有工具组件。持续性功能障碍的定义是,在 6 个月的访谈中,根据七项日常活动,未能恢复到入住重症监护病房前的功能基线。在添加了三个院内因素作为预测因子后,对模型进行了依次重拟,每次添加一个,然后再一起添加。结果该工具达到了先验可行性阈值,92.0%的参与者完成了所有八个组成部分。在探索性分析中,加入急性生理学和慢性健康评估 II 评分、谵妄的存在和院内最大活动能力后,辨别率提高了 5%,但未达到统计学意义(接收器操作特征曲线下面积,0.75;95% CI,0.68-0.82;P = 0.09)。解释我们的结果表明,风险预测工具在医院环境中的使用是可行的,可以识别出出院后 6 个月仍有持续功能障碍高风险的 ICU 幸存者。医院相关因素的增强提高了模型的区分度,但在这项试点研究中并没有达到统计学意义。未来的研究应该在更大的群体中对增强模型进行评估。
{"title":"Feasibility of In-Hospital Administration of a Tool to Predict Persistent Post-ICU Functional Impairment Among Older ICU Survivors","authors":"Julia A. Stevenson BA ,&nbsp;Terrence E. Murphy PhD ,&nbsp;Baylah Tessier-Sherman MPH ,&nbsp;Margaret A. Pisani MD, MPH ,&nbsp;Thomas M. Gill MD ,&nbsp;Lauren E. Ferrante MD, MHS","doi":"10.1016/j.chstcc.2024.100093","DOIUrl":"10.1016/j.chstcc.2024.100093","url":null,"abstract":"<div><h3>Background</h3><div>A recent international consensus conference called for the development of risk prediction models to identify ICU survivors at increased risk of each of the post-ICU syndrome domains. We previously developed and validated a risk prediction tool for functional impairment after ICU admission among older adults.</div></div><div><h3>Research Question</h3><div>In this pilot study, we assessed the feasibility of administering the risk prediction tool in the hospital to older adults who had just survived critical illness. An exploratory objective was to evaluate whether augmentation of the model with additional hospital-related factors improved discrimination.</div></div><div><h3>Study Design and Methods</h3><div>Between January and October 2020, 50 adults aged 65 years and older underwent in-hospital administration of the risk prediction tool. Survivors were called monthly for 6 months after discharge. Feasibility was defined as completion of all tool components by ≥ 70% of enrolled participants. Persistent functional impairment was defined as failure to return to the functional baseline from before the ICU stay at the 6-month interview based on seven daily activities. The model was sequentially refit after adding three in-hospital factors as predictors, one at a time and then all together. Model discrimination was assessed with receiver operating characteristic curves.</div></div><div><h3>Results</h3><div>The tool met the a priori feasibility threshold, with 92.0% of enrolled participants completing all eight components. In the exploratory analysis, the addition of Acute Physiology and Chronic Health Evaluation II score, presence of delirium, and maximum in-hospital mobility resulted in a 5% gain in discrimination that did not achieve statistical significance (area under the receiver operating characteristic curve, 0.75; 95% CI, 0.68-0.82; <em>P</em> = .09).</div></div><div><h3>Interpretation</h3><div>Our results indicate that the risk prediction tool is feasible for use in the hospital setting, enabling the identification of ICU survivors at high risk of persistent functional impairment at 6 months after discharge. Augmentation with hospital-related factors improved model discrimination, but did not achieve statistical significance in this pilot study. Future studies should evaluate the augmented model in larger cohorts.</div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 4","pages":"Article 100093"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sugar Rush 糖瘾:我们离了解糖尿病与 ARDS 之间的关系又近了一步吗?
Pub Date : 2024-07-14 DOI: 10.1016/j.chstcc.2024.100090
Andrew J. Boyle PhD , Adam M. Deane PhD
{"title":"Sugar Rush","authors":"Andrew J. Boyle PhD ,&nbsp;Adam M. Deane PhD","doi":"10.1016/j.chstcc.2024.100090","DOIUrl":"10.1016/j.chstcc.2024.100090","url":null,"abstract":"","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 3","pages":"Article 100090"},"PeriodicalIF":0.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949788424000443/pdfft?md5=7f17d804f410309f213fddc342bdfb21&pid=1-s2.0-S2949788424000443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141696189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mind the Gap 注意差距
Pub Date : 2024-07-06 DOI: 10.1016/j.chstcc.2024.100089
Isabel A. Mangaoang PharmD , Kendra J. Schomer PharmD , Rachelle L. Firestone PharmD , Jeremiah J. Duby PharmD

Background

Induction agents are administered to decrease the risk of discomfort, awareness, and psychological sequelae during procedural paralysis (eg, rapid sequence intubation). The expected duration of nondepolarizing neuromuscular blocking agents exceeds that of induction sedatives. The resulting sedation gap may increase the risk of awake paralysis.

Research Question

The objective of this study was to elucidate the prevalence and duration of sedation gaps in critically ill patients undergoing bedside procedural paralysis.

Study Design and Methods

This was a retrospective cross-sectional study of critically ill adults who received rocuronium for a bedside procedure. The primary outcome was the sedation gap, which was the cumulative time of inadequate sedation during presumed paralysis (ie, 60 min after rocuronium). Secondary outcomes included the sedation gap when a pharmacist was present at the bedside. Descriptive statistics were used for baseline characteristics and the primary outcome. Log-rank and Mann-Whitney U tests were used to analyze secondary outcomes.

Results

Eighty patients were included in the final analysis. The average age was 60 years and 57% of patients were male. The most common indication for procedural paralysis was rapid sequence intubation (99%). Most procedures were performed in the ED (55%), followed by the ICU (43.8%). Eighty-five percent of patients experienced a sedation gap of any duration. The median sedation gap was 19 min (interquartile range [IQR], 4-47.5 min). The probability of initiating adequate sedation was higher when a pharmacist was present at the bedside (hazard ratio, 1.49 [95% CI, 1.42-1.55], bootstrapping log-rank test). The median sedation gap with a pharmacist (11 min [IQR, 3-27.5 min]) was significantly lower than without a pharmacist (40 min [IQR, 17-55 min]; P = .0115, Mann-Whitney U test).

Interpretation

In this critically ill cohort, a substantial prevalence and duration of inadequate sedation was experienced after receiving rocuronium for bedside procedures. Further study is needed to identify if sedation gaps correlate with an increased risk of psychological morbidities.

背景使用诱导剂是为了降低手术瘫痪(如快速顺序插管)过程中出现不适、意识障碍和心理后遗症的风险。非去极化神经肌肉阻滞剂的预期持续时间超过诱导镇静剂。研究设计与方法这是一项回顾性横断面研究,研究对象为接受罗库洛铵治疗的重症成人患者。主要结果是镇静间隙,即假定瘫痪期间(即罗库洛铵作用后 60 分钟)镇静不足的累计时间。次要结果包括药剂师在床旁时的镇静间隙。基线特征和主要结果采用描述性统计。对数秩检验和曼惠尼 U 检验用于分析次要结果。平均年龄为 60 岁,57% 的患者为男性。手术麻痹最常见的适应症是快速顺序插管(99%)。大多数手术在急诊室进行(55%),其次是重症监护室(43.8%)。85%的患者经历过任何时间段的镇静间隙。镇静间隙的中位数为 19 分钟(四分位距 [IQR],4-47.5 分钟)。有药剂师在床旁时,启动充分镇静的概率更高(危险比为 1.49 [95% CI, 1.42-1.55],引导对数秩检验)。有药剂师在场时,镇静间隙的中位数(11 分钟 [IQR, 3-27.5 分钟])明显低于无药剂师在场时(40 分钟 [IQR, 17-55 分钟];P = .0115, Mann-Whitney U 检验)。需要进一步研究以确定镇静不足是否与心理疾病风险增加有关。
{"title":"Mind the Gap","authors":"Isabel A. Mangaoang PharmD ,&nbsp;Kendra J. Schomer PharmD ,&nbsp;Rachelle L. Firestone PharmD ,&nbsp;Jeremiah J. Duby PharmD","doi":"10.1016/j.chstcc.2024.100089","DOIUrl":"10.1016/j.chstcc.2024.100089","url":null,"abstract":"<div><h3>Background</h3><p>Induction agents are administered to decrease the risk of discomfort, awareness, and psychological sequelae during procedural paralysis (eg, rapid sequence intubation). The expected duration of nondepolarizing neuromuscular blocking agents exceeds that of induction sedatives. The resulting sedation gap may increase the risk of awake paralysis.</p></div><div><h3>Research Question</h3><p>The objective of this study was to elucidate the prevalence and duration of sedation gaps in critically ill patients undergoing bedside procedural paralysis.</p></div><div><h3>Study Design and Methods</h3><p>This was a retrospective cross-sectional study of critically ill adults who received rocuronium for a bedside procedure. The primary outcome was the sedation gap, which was the cumulative time of inadequate sedation during presumed paralysis (ie, 60 min after rocuronium). Secondary outcomes included the sedation gap when a pharmacist was present at the bedside. Descriptive statistics were used for baseline characteristics and the primary outcome. Log-rank and Mann-Whitney <em>U</em> tests were used to analyze secondary outcomes.</p></div><div><h3>Results</h3><p>Eighty patients were included in the final analysis. The average age was 60 years and 57% of patients were male. The most common indication for procedural paralysis was rapid sequence intubation (99%). Most procedures were performed in the ED (55%), followed by the ICU (43.8%). Eighty-five percent of patients experienced a sedation gap of any duration. The median sedation gap was 19 min (interquartile range [IQR], 4-47.5 min). The probability of initiating adequate sedation was higher when a pharmacist was present at the bedside (hazard ratio, 1.49 [95% CI, 1.42-1.55], bootstrapping log-rank test). The median sedation gap with a pharmacist (11 min [IQR, 3-27.5 min]) was significantly lower than without a pharmacist (40 min [IQR, 17-55 min]; <em>P</em> = .0115, Mann-Whitney <em>U</em> test).</p></div><div><h3>Interpretation</h3><p>In this critically ill cohort, a substantial prevalence and duration of inadequate sedation was experienced after receiving rocuronium for bedside procedures. Further study is needed to identify if sedation gaps correlate with an increased risk of psychological morbidities.</p></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 3","pages":"Article 100089"},"PeriodicalIF":0.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949788424000431/pdfft?md5=d3ad7f3d4078c5c0f5f838adea87b630&pid=1-s2.0-S2949788424000431-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142084168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Move Away From Arbitrariness 摒弃任意性
Pub Date : 2024-06-22 DOI: 10.1016/j.chstcc.2024.100087
Somnath Bose MD, MPH
{"title":"Move Away From Arbitrariness","authors":"Somnath Bose MD, MPH","doi":"10.1016/j.chstcc.2024.100087","DOIUrl":"10.1016/j.chstcc.2024.100087","url":null,"abstract":"","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"2 3","pages":"Article 100087"},"PeriodicalIF":0.0,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949788424000418/pdfft?md5=5af924eb432cf96f9c98a6cc7c923ff6&pid=1-s2.0-S2949788424000418-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142084167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
CHEST critical care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1